Dicerna Pharmaceuticals, Inc. Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

CAMBRIDGE, Mass.--()--Dicerna Pharmaceuticals, Inc. (NASDAQ: DRNA), a leader in the development of RNA interference-based therapeutics targeting rare inherited diseases involving the liver and for cancers that are genetically defined, today announced that on June 30, 2015, the Compensation Committee of the Company's Board of Directors approved the grant of inducement stock options to purchase a total of 115,500 shares of common stock to four new employees, with all four grants having a grant date of June 30, 2015 (the "Q2 2015 Inducement Grants").

Each of the Q2 2015 Inducement Grants has an exercise price per share equal to $13.95, the fair market value on the grant date. Each stock option vests over four years, with 25% vesting on the one-year anniversary of the employee's first day of employment with the Company and 1/48 of the shares vesting monthly thereafter, subject to the new employee's continued service relationship with the Company on each such date. Each stock option has a ten year term and is subject to the terms and conditions of the applicable stock option agreement.

Each of the stock options was granted as an inducement material to the new employees entering into employment with Dicerna Pharmaceuticals, Inc. in accordance with NASDAQ listing Rule 5635(c)(4).

About Dicerna Pharmaceuticals, Inc.

Dicerna is a biopharmaceutical company focused on the discovery and development of innovative treatments for rare inherited diseases involving the liver and for cancers that are genetically defined. The Company is using its proprietary RNA interference technology platform to build a broad pipeline in these therapeutic areas. In both rare diseases and oncology, Dicerna is pursuing targets that have historically been difficult to inhibit using conventional approaches, but where connections between targets and diseases are well understood and documented. The Company intends to discover, develop and commercialize novel therapeutics either on its own or in collaboration with pharmaceutical partners. For more information, please visit www.dicerna.com.

Cautionary Note on Forward-Looking Statements

This press release includes forward-looking statements. Such forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied in such statements. Applicable risks and uncertainties include those relating to our preclinical research and other risks identified under the heading "Risk Factors" included in our most recent Form 10-Q filing and in subsequent and future filings with the SEC. The forward-looking statements contained in this press release reflect Dicerna's current views with respect to future events, and Dicerna does not undertake and specifically disclaims any obligation to update any forward-looking statements.

Contacts

Investor Contact:
Westwicke Partners
Peter Vozzo, 443-213-0505
peter.vozzo@westwicke.com
or
Media Contact:
SmithSolve
Alex Van Rees, 973-442-1555 ext. 111
alex.vanrees@smithsolve.com

Dicerna Pharmaceuticals, Inc.